Poll results: Preferred treatment plans for mild-stage POAG

Article

See our latest poll results

Optometry Times® polled our audience with the following question from January 28, 2022 to February 11, 2022:​ If diagnosed with mild-stage POAG, what would be your preferred treatment plan?

The poll appeared on optometrytimes.com and was promoted on social media channels. Results show the majority of responding ODs would initiate medical therapy with a topical glaucoma medication.

22 ODs responded, in total. Of these:

  • 15 responded "Initiate medical therapy with a topical glaucoma medication"
  • 4 responded "Have selective laser trabeculoplasty (SLT)"
  • 3 responded "Have a minimally invasive glaucoma surgery (MIGS)"

Check out our latest poll: What is your big goal for 2022?

Recent Videos
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Shan Lin, MD, and John Berdahl, MD, share their perspectives as ophthalmologists regarding the importance of comanagement.
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
John Berdahl, MD, overviews the new FYXS Ocular Pressure Adjusting Pump and HERCULES trial at the Glaucoma 360 meeting.
Shan Lin, MD, outlines a new generation of minimally invasive glaucoma surgeries (MIGS) at Glaucoma 360.
Danica Marrelli, OD, FAAO, at Glaucoma 360 discussing visual field testing for patients with glaucoma
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
© 2025 MJH Life Sciences

All rights reserved.